Teon Therapeutics is a biopharmaceutical company that discovers and develops oral cancer medications for restoring anti-tumor immunity. Its pipeline targets unexploited metabolic pathways and includes TT-816, a small molecule cannabinoid CB2 receptor antagonist acting as a immune response modifier, and TT-702, an A2B selective adenosine receptor antagonist.